JP2010538052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010538052A5 JP2010538052A5 JP2010523577A JP2010523577A JP2010538052A5 JP 2010538052 A5 JP2010538052 A5 JP 2010538052A5 JP 2010523577 A JP2010523577 A JP 2010523577A JP 2010523577 A JP2010523577 A JP 2010523577A JP 2010538052 A5 JP2010538052 A5 JP 2010538052A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- group
- compound
- optionally substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 91
- 125000001424 substituent group Chemical group 0.000 claims 49
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical class 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 229910052731 fluorine Inorganic materials 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 238000006243 chemical reaction Methods 0.000 claims 12
- 239000000460 chlorine Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 229910052801 chlorine Inorganic materials 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- -1 3-nitro-4-aminophenyl Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 239000002671 adjuvant Substances 0.000 claims 7
- 239000003085 diluting agent Substances 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 208000023504 respiratory system disease Diseases 0.000 claims 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 208000024780 Urticaria Diseases 0.000 claims 4
- 150000001340 alkali metals Chemical group 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 239000013066 combination product Substances 0.000 claims 3
- 229940127555 combination product Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 238000003786 synthesis reaction Methods 0.000 claims 3
- 229910052725 zinc Inorganic materials 0.000 claims 3
- 239000011701 zinc Substances 0.000 claims 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 claims 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 208000028185 Angioedema Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 208000004221 Multiple Trauma Diseases 0.000 claims 2
- 208000023637 Multiple injury Diseases 0.000 claims 2
- 208000031888 Mycoses Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 208000025747 Rheumatic disease Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010051222 Toxic oil syndrome Diseases 0.000 claims 2
- 208000012931 Urologic disease Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000029771 childhood onset asthma Diseases 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 230000002327 eosinophilic effect Effects 0.000 claims 2
- 208000019097 eosinophilic gastrointestinal disease Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000007062 hydrolysis Effects 0.000 claims 2
- 238000006460 hydrolysis reaction Methods 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- 230000004792 oxidative damage Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 208000014001 urinary system disease Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 150000002366 halogen compounds Chemical class 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000020477 pH reduction Effects 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 230000006103 sulfonylation Effects 0.000 claims 1
- 238000005694 sulfonylation reaction Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 238000005809 transesterification reaction Methods 0.000 claims 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93584907P | 2007-09-04 | 2007-09-04 | |
| PCT/GB2008/002964 WO2009030887A2 (en) | 2007-09-04 | 2008-09-03 | Bis-aromatic compounds useful in the treatment of inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010538052A JP2010538052A (ja) | 2010-12-09 |
| JP2010538052A5 true JP2010538052A5 (enExample) | 2011-10-20 |
Family
ID=40243899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523577A Withdrawn JP2010538052A (ja) | 2007-09-04 | 2008-09-03 | 炎症の治療に有用な二芳香族化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100286215A1 (enExample) |
| EP (1) | EP2185504A2 (enExample) |
| JP (1) | JP2010538052A (enExample) |
| KR (1) | KR20100067102A (enExample) |
| CN (1) | CN101835741A (enExample) |
| AU (1) | AU2008294535A1 (enExample) |
| BR (1) | BRPI0816320A2 (enExample) |
| CA (1) | CA2698847A1 (enExample) |
| EA (1) | EA201000422A1 (enExample) |
| MX (1) | MX2010002521A (enExample) |
| NZ (1) | NZ583642A (enExample) |
| WO (1) | WO2009030887A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110112193A1 (en) * | 2008-05-14 | 2011-05-12 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
| TW201036946A (en) * | 2009-01-30 | 2010-10-16 | Toyama Chemical Co Ltd | N-acylanthranilic acid derivative or salt thereof |
| JP2012520276A (ja) * | 2009-03-12 | 2012-09-06 | バイオリポックス エービー | Ｌｔｃ４シンターゼ阻害剤としての使用のためのビス芳香族化合物 |
| CA2754941A1 (en) | 2009-03-12 | 2010-09-16 | Biolipox Ab | Bis aromatic compounds for use as ltc4 synthase inhibitors |
| CA2754946A1 (en) | 2009-03-12 | 2010-09-16 | Biolipox Ab | Bis aromatic compounds for use as ltc4 synthase inhibitors |
| CN102348686A (zh) * | 2009-03-12 | 2012-02-08 | 比奥里波克斯公司 | 用作ltc4合酶抑制剂的双芳族化合物 |
| CN102656141B (zh) | 2009-10-13 | 2016-04-06 | 利亘制药公司 | 模拟造血生长因子的小分子化合物及其用途 |
| EP2545036A1 (en) | 2010-03-12 | 2013-01-16 | Biolipox AB | Bis aromatic compounds for use as ltc4 synthase inhibitors |
| GB201507753D0 (en) | 2015-05-06 | 2015-06-17 | Biolipox Ab | New compounds and uses |
| BR112020001327A2 (pt) | 2017-07-21 | 2020-08-11 | Antabio Sas | compostos químicos |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| KR102867888B1 (ko) | 2018-01-31 | 2025-10-13 | 데시페라 파마슈티칼스, 엘엘씨 | 비만 세포증의 치료를 위한 병용 요법 |
| AU2019232437A1 (en) | 2018-03-07 | 2020-10-08 | Bayer Aktiengesellschaft | Identification and use of ERK5 inhibitors |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| IL293866A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Compositions of amorphous kinase inhibitors and methods of using them |
| KR20250057151A (ko) | 2019-12-30 | 2025-04-28 | 데시페라 파마슈티칼스, 엘엘씨 | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물 |
| BR112023002031A2 (pt) | 2020-08-14 | 2023-03-07 | Novartis Ag | Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2495343B1 (fr) * | 1980-12-02 | 1987-02-20 | Regma | Materiaux diazotypes thermodeveloppables contenant un precurseur d'activateur liberant lors du chauffage une base forte. procede de diazotypie mettant en oeuvre ces materiaux |
| US4992576A (en) * | 1987-01-12 | 1991-02-12 | Eli Lilly And Company | Intermediates for leukotriene antagonists |
| CA1320490C (en) * | 1987-01-12 | 1993-07-20 | Darrel M. Gapinski | Anti-inflammatory agents |
| US4892578A (en) * | 1987-11-06 | 1990-01-09 | Fmc Corporation | Phenylmethyl-4,4-dimethyl-3-isoxazolidinone plant regulators |
| CN100378063C (zh) * | 1998-11-05 | 2008-04-02 | 富山化学工业株式会社 | 新型化合物及其医药用途 |
| US7264932B2 (en) * | 1999-09-24 | 2007-09-04 | Applera Corporation | Nuclease inhibitor cocktail |
| US6590118B1 (en) * | 1999-09-29 | 2003-07-08 | Novo Nordisk A/S | Aromatic compounds |
| EP1220832A1 (en) * | 1999-09-29 | 2002-07-10 | Novo Nordisk A/S | Novel aromatic compounds |
| US20030097010A1 (en) * | 2001-09-27 | 2003-05-22 | Vogel Dennis E. | Process for preparing pentacene derivatives |
| JP4948173B2 (ja) * | 2003-10-10 | 2012-06-06 | ニツポネツクス・インコーポレーテツド | 過剰増殖性疾患治療用ピリミジン誘導体 |
| DE10349587A1 (de) * | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| PL1771450T3 (pl) * | 2004-05-14 | 2008-05-30 | Millennium Pharm Inc | Związki i sposoby do inhibicji postępu mitozy przez hamowanie kinazy Aurora |
-
2008
- 2008-09-03 CA CA2698847A patent/CA2698847A1/en not_active Abandoned
- 2008-09-03 NZ NZ583642A patent/NZ583642A/en not_active IP Right Cessation
- 2008-09-03 AU AU2008294535A patent/AU2008294535A1/en not_active Abandoned
- 2008-09-03 EA EA201000422A patent/EA201000422A1/ru unknown
- 2008-09-03 JP JP2010523577A patent/JP2010538052A/ja not_active Withdrawn
- 2008-09-03 BR BRPI0816320-0A patent/BRPI0816320A2/pt not_active IP Right Cessation
- 2008-09-03 WO PCT/GB2008/002964 patent/WO2009030887A2/en not_active Ceased
- 2008-09-03 CN CN200880112774A patent/CN101835741A/zh active Pending
- 2008-09-03 KR KR1020107007264A patent/KR20100067102A/ko not_active Withdrawn
- 2008-09-03 MX MX2010002521A patent/MX2010002521A/es unknown
- 2008-09-03 US US12/676,575 patent/US20100286215A1/en not_active Abandoned
- 2008-09-03 EP EP08788506A patent/EP2185504A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010538052A5 (enExample) | ||
| JP2011520785A5 (enExample) | ||
| JP2006512301A5 (enExample) | ||
| ES2254470T3 (es) | Compuestos inmunorreguladores, derivados de los mismos y su uso. | |
| CN106518924B (zh) | 用于治疗nk-1受体相关疾病的取代的4-苯基吡啶 | |
| JP2010538052A (ja) | 炎症の治療に有用な二芳香族化合物 | |
| JP2010520268A5 (enExample) | ||
| JP2006513268A5 (ja) | アンタゴニスト活性を有するベンゾアゾリルピペラジン誘導体 | |
| CN105228451B (zh) | 制备具有硫醇连接子和聚乙二醇化形式的前列环素化合物的方法 | |
| JPH0121139B2 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| ES2249015T3 (es) | Derivados de 2-aminopiridinas, su utilizacion como medicamentos y composiciones farmaceuticas que los contienen. | |
| JP2009532417A5 (enExample) | ||
| WO2015000431A1 (zh) | 替唑尼特氨基甲酸酯及其在药学中的应用 | |
| CN1310721A (zh) | 药物硝酸盐 | |
| WO2013053739A1 (en) | Process for preparing factor xa inhibitors | |
| JP2002505328A (ja) | 抗潰瘍医薬の硝酸塩 | |
| JP2008520662A5 (enExample) | ||
| ES2791187T3 (es) | Síntesis de dabigatrán | |
| JP2017537957A (ja) | 置換されたピリジル−シクロアルキル−カルボン酸類、それらを含む組成物およびそれらの医学的使用 | |
| CN104311514A (zh) | 3-羟甲基四氢呋喃酯的合成方法 | |
| WO2002094829A1 (en) | Carbapenem compound | |
| JP2012502984A (ja) | アデホビルジピボキシルの改善された製造方法 | |
| JP2007519685A5 (enExample) | ||
| JP2017523216A (ja) | ダプソン及びその中間体を合成する方法 |